UBS AM
HQL

UBS AM’s abrdn Life Sciences Investors HQL Stock Holding History

UBS AM’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260 Hold
13
– – ﹤0.01% 3689
2026
Q1 		$212 Buy
+13
New +$217 ﹤0.01% 3776

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

UBS AM's HQL Position: Q2 2026 in Review

UBS AM held its abrdn Life Sciences Investors (HQL) position steady in Q2 2026 at 13 shares worth $260. The position accounts for ﹤0.01% of the portfolio, ranked #3689.

UBS AM first reported a position in HQL in Q1 2026 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • UBS AM held 13 shares of abrdn Life Sciences Investors worth $260 as of Q2 2026.
  • UBS AM left its abrdn Life Sciences Investors share count unchanged in Q2 2026.
  • abrdn Life Sciences Investors made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3689 holding.
  • UBS AM first reported a position in abrdn Life Sciences Investors in Q1 2026 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.